Folgen
Paolo Manca
Paolo Manca
Research Scholar MSK - Oncology Resident INT Milan
Bestätigte E-Mail-Adresse bei mskcc.org
Titel
Zitiert von
Zitiert von
Jahr
Circulating tumor DNA to guide rechallenge with panitumumab in metastatic colorectal cancer: the phase 2 CHRONOS trial
A Sartore-Bianchi, F Pietrantonio, S Lonardi, B Mussolin, F Rua, ...
Nature Medicine 28 (8), 1612-1618, 2022
1482022
Exosomes as diagnostic and predictive biomarkers in lung cancer
P Reclusa, S Taverna, M Pucci, E Durendez, S Calabuig, P Manca, ...
Journal of thoracic disease 9 (Suppl 13), S1373, 2017
1242017
Multidisciplinary molecular tumour board: a tool to improve clinical practice and selection accrual for clinical trials in patients with cancer
C Rolfo, P Manca, R Salgado, P Van Dam, A Dendooven, JF Gandia, ...
ESMO open 3 (5), e000398, 2018
982018
Phase II study of anti-EGFR rechallenge therapy with panitumumab driven by circulating tumor DNA molecular selection in metastatic colorectal cancer: The CHRONOS trial.
A Sartore-Bianchi, F Pietrantonio, S Lonardi, B Mussolin, F Rua, ...
Journal of Clinical Oncology 39 (15_suppl), 3506-3506, 2021
652021
Extracellular vesicle PD-L1 dynamics predict durable response to immune-checkpoint inhibitors and survival in patients with non-small cell lung cancer
D de Miguel-Perez, A Russo, O Arrieta, M Ak, F Barron, M Gunasekaran, ...
Journal of Experimental & Clinical Cancer Research 41 (1), 186, 2022
632022
Cabozantinib targets bone microenvironment modulating human osteoclast and osteoblast functions
M Fioramonti, D Santini, M Iuliani, G Ribelli, P Manca, N Papapietro, ...
Oncotarget 8 (12), 20113, 2017
412017
Determinants of bone specific metastasis in prostate cancer
P Manca, F Pantano, M Iuliani, G Ribelli, D De Lisi, R Danesi, M Del Re, ...
Critical Reviews in Oncology/Hematology 112, 59-66, 2017
252017
Negative Ultraselection of Patients With RAS/BRAF Wild-Type, Microsatellite-Stable Metastatic Colorectal Cancer Receiving Anti–EGFR-Based Therapy
G Randon, G Maddalena, MM Germani, CC Pircher, P Manca, F Bergamo, ...
JCO Precision Oncology 6, e2200037, 2022
232022
Rationale and study design of the PARERE trial: randomized phase II study of panitumumab re-treatment followed by regorafenib versus the reverse sequence in RAS and BRAF wild …
R Moretto, D Rossini, I Capone, A Boccaccino, F Perrone, E Tamborini, ...
Clinical Colorectal Cancer 20 (4), 314-317, 2021
212021
EGFR Amplification in Metastatic Colorectal Cancer
G Randon, R Yaeger, JF Hechtman, P Manca, G Fucà, H Walch, J Lee, ...
JNCI: Journal of the National Cancer Institute 113 (11), 1561-1569, 2021
212021
Impact of early tumor shrinkage and depth of response on the outcomes of panitumumab-based maintenance in patients with RAS wild-type metastatic colorectal cancer
P Manca, S Corallo, G Randon, S Lonardi, C Cremolini, L Rimassa, ...
European Journal of Cancer 144, 31-40, 2021
212021
Circulating tumor DNA as a marker of minimal residual disease after radical resection of colorectal liver metastases
F Marmorino, M Prisciandaro, M Giordano, E Ortolan, S Crucitta, P Manca, ...
JCO precision oncology 6, e2200244, 2022
202022
Variant allele frequency in baseline circulating tumour DNA to measure tumour burden and to stratify outcomes in patients with RAS wild-type metastatic colorectal …
P Manca, S Corallo, S Lonardi, G Fucà, A Busico, AG Leone, F Corti, ...
British Journal of Cancer 126 (3), 449-455, 2022
202022
Prognostic impact of early tumor shrinkage and depth of response in patients with microsatellite instability-high metastatic colorectal cancer receiving immune checkpoint …
G Fucà, F Corti, M Ambrosini, R Intini, M Salati, E Fenocchio, P Manca, ...
Journal for Immunotherapy of Cancer 9 (4), 2021
192021
Large-scale profiling of extracellular vesicles identified miR-625-5p as a novel biomarker of immunotherapy response in advanced non-small-cell lung cancer patients
F Pantano, F Zalfa, M Iuliani, S Simonetti, P Manca, A Napolitano, S Tiberi, ...
Cancers 14 (10), 2435, 2022
162022
Phase I trial characterizing the pharmacokinetic profile of N-803, a chimeric IL-15 superagonist, in healthy volunteers
MP Rubinstein, C Williams, C Mart, J Beall, L MacPherson, J Azar, ...
The Journal of Immunology 208 (6), 1362-1370, 2022
162022
Tumour mutational burden predicts resistance to EGFR/BRAF blockade in BRAF-mutated microsatellite stable metastatic colorectal cancer
G Randon, R Intini, C Cremolini, E Elez, MJ Overman, J Lee, P Manca, ...
European Journal of Cancer 161, 90-98, 2022
162022
The added value of baseline circulating tumor DNA profiling in patients with molecularly hyperselected, left-sided metastatic colorectal cancer
P Manca, S Corallo, A Busico, S Lonardi, F Corti, C Antoniotti, L Procaccio, ...
Clinical Cancer Research 27 (9), 2505-2514, 2021
162021
The value of immunotherapy in head and neck cancer
P Manca, LE Raez, M Salzberg, J Sanchez, B Hunis, C Rolfo
Expert Opinion on Biological Therapy 19 (1), 35-43, 2019
162019
Tumour mutational burden as a biomarker in patients with mismatch repair deficient/microsatellite instability-high metastatic colorectal cancer treated with immune checkpoint …
P Manca, F Corti, R Intini, G Mazzoli, R Miceli, MM Germani, F Bergamo, ...
European Journal of Cancer 187, 15-24, 2023
152023
Das System kann den Vorgang jetzt nicht ausführen. Versuchen Sie es später erneut.
Artikel 1–20